Ventyx Biosciences Company Insiders

VTYX Stock  USD 1.32  0.01  0.75%   
Ventyx Biosciences employs about 79 people. The company is managed by 11 executives with a total tenure of roughly 185 years, averaging almost 16.0 years of service per executive, having 7.18 employees per reported executive. Break down of Ventyx Biosciences' management performance can provide insight into the company performance.

Insider Sentiment 50

 Impartial

 
Selling
 
Buying

Latest Trades

2024-12-27John NussDisposed 21119 @ 2.36View
2024-12-23Sheila GujrathiAcquired 130000 @ 2.31View
2024-12-19John NussDisposed 13161 @ 2.26View
2024-11-25Raju MohanAcquired 261752 @ 2.01View
2024-11-22Raju MohanAcquired 238248 @ 1.83View
2024-04-02Raju MohanDisposed 4312 @ 5.4View
Monitoring Ventyx Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Ventyx Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Ventyx Stock please use our How to Invest in Ventyx Biosciences guide.

Ventyx Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.3348) % which means that it has lost $0.3348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5427) %, meaning that it created substantial loss on money invested by shareholders. Ventyx Biosciences' management efficiency ratios could be used to measure how well Ventyx Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to rise to -0.53 in 2025. At this time, Ventyx Biosciences' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 38.5 M in 2025, whereas Total Assets are likely to drop slightly above 223.3 M in 2025.
Common Stock Shares Outstanding is likely to drop to about 60.6 M in 2025. Net Loss is likely to rise to about (92.7 M) in 2025

Ventyx Biosciences Workforce Comparison

Ventyx Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,654. Ventyx Biosciences claims roughly 79.0 in number of employees contributing just under 2% to equities under Health Care industry.

Ventyx Biosciences Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ventyx Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ventyx Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ventyx Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Ventyx Biosciences Notable Stakeholders

A Ventyx Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ventyx Biosciences often face trade-offs trying to please all of them. Ventyx Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ventyx Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Raju MohanCEO, FounderProfile
Matthew MooreChief OfficerProfile
Snehal NaikSenior DevelopmentProfile
Kye MDData BiostatisticsProfile
Sheila MDExecutive ChairpersonProfile
John NussChief OfficerProfile
Martin MDChief OfficerProfile
Kathy OgilvieSenior ResearchProfile
Prof MDPres OfficerProfile
Rosa FerraoSenior AffairsProfile
MBA JDChief OfficerProfile

About Ventyx Biosciences Management Performance

The success or failure of an entity such as Ventyx Biosciences often depends on how effective the management is. Ventyx Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ventyx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ventyx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.49)(0.51)
Return On Capital Employed(0.56)(0.53)
Return On Assets(0.49)(0.51)
Return On Equity(0.53)(0.51)
Please note, the imprecision that can be found in Ventyx Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ventyx Biosciences. Check Ventyx Biosciences' Beneish M Score to see the likelihood of Ventyx Biosciences' management manipulating its earnings.

Ventyx Biosciences Workforce Analysis

Traditionally, organizations such as Ventyx Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ventyx Biosciences within its industry.

Ventyx Biosciences Manpower Efficiency

Return on Ventyx Biosciences Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.7M
Net Loss Per Executive12.3M
Working Capital Per Employee2.7M
Working Capital Per Executive19.7M

Additional Tools for Ventyx Stock Analysis

When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.